GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
G

Guhan Pharmaceutical Group Co 000590.SZ · CNY

Health Care · Shenzhen · 🇨🇳 China

Compare

7.66

-2.54%

Close of 9 Nov 2026, in CNY

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

About Guhan Pharmaceutical Group Co

Its shares trade on Shenzhen under the ticker 000590.SZ. It has been listed since 19 January 1996. In the fiscal year to 31 December 2025, it reported revenue of CN¥337.7m and a net loss of CN¥50.5m. At that date it held total assets of CN¥889.5m and shareholders' equity of CN¥547.6m.

Tus-Pharmaceutical Group Co., Ltd. engages in the research and development, production and sales of Chinese patent medicine. The company is headquartered in Hengyang, Hunan. The firm provides Chinese medicines, including Chinese healthcare products, medicines for cold treatment and anti hyperlipemia medicines, among others. The company also provides western medicine preparations, including clindamycin phosphate for injection, lomefloxacin hydrochloride for injection and levofloxacin lactate for injection, among others. The firm distributes its products in domestic markets.

Figures and description from our data supplier, not checked against the company's own report.

Company facts

Sector
Health Care
Industry
Pharmaceuticals
Listed since
19 Jan 1996
Employees
1,309

Leadership

Pay as last reported

  • Mr. Qisen JiaoChairman of the Board, Acting Secretary of the Board, since 2020
  • Mr. Xue FengPresident, Director, since 2020
  • Ruizhi YuanChief Financial OfficerCN¥240,000
  • Mr. Jun CaiSenior Vice President
  • Mr. Ge WenSenior Vice President
  • Mr. Chengliang LiuVice President
  • Mr. Wenbiao HuangIndependent Director
  • Mr. Zhenhua LeiIndependent Director

Environmental, social and governance

Scores out of 100, from our data supplier

ESG
Overall
0
Environment
0
Social
0
Governance
0

SWOT analysis

AI-generated by our data supplier. Not written or checked by our editors.

AI-generated

Strengths

  • Guhan Pharmaceutical Group employs 1309 full-time staff members in Hengyang.
  • The company produces Chinese patent medicines for domestic markets.
  • Western medicine preparations include clindamycin phosphate for injection.

Weaknesses

  • Products are distributed only in domestic markets.
  • Reliance on Chinese patent medicine limits diversity.
  • Hengyang location may restrict international expansion efforts.

Opportunities

  • Expanding western medicine sales could increase revenue.
  • Growing demand for cold treatment medicines offers growth.
  • Healthcare products segment presents new market potential.

Threats

  • Domestic market saturation may limit future growth.
  • Competition in Chinese patent medicine is intense.
  • Regulatory changes could impact production costs.

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.